Tags

Type your tag names separated by a space and hit enter

Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial.
Nutrients. 2019 Oct 22; 11(10)N

Abstract

Some coauthors of this study previously performed the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2,000 IU/day) in 417 patients with stage I to III digestive tract cancer from the esophagus to the rectum who underwent curative surgery (UMIN000001977). We conducted a post-hoc analysis of the AMATERASU trial to explore the effects of modification of vitamin D supplementation by histopathological characteristics on survival. Among patients with poorly differentiated adenocarcinoma, the 5-year relapse-free survival rate of patients supplemented with vitamin D was 91% compared with 63% in the placebo group (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.08 to 0.78; P = 0.017; P for interaction = 0.023). Similarly, the 5-year overall survival rate was 92% in the vitamin D group compared with 72% in the placebo group (HR, 0.25; 95%CI, 0.07 to 0.94; P = 0.040; P for interaction = 0.012). In contrast, there were no significant effects in other histopathological characteristics between vitamin D and placebo groups. These findings generated the hypothesis that oral vitamin D supplementation may improve both relapse-free survival and overall survival in a subgroup of patients with poorly differentiated adenocarcinoma.

Authors+Show Affiliations

Division of Molecular Epidemiology, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo 105-8461, Japan. yonaga_h@jikei.ac.jp. Celgene K. K., JP TOWER 2-7-2 Marunouchi Chiyoda-ku, Tokyo 100-7010, Japan. yonaga_h@jikei.ac.jp.Department of Pathology, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, Japan. shinya1012@iuhw.ac.jp.Division of Molecular Epidemiology, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo 105-8461, Japan. taisuke0107.jusom@gmail.com.Department of Surgery, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, Japan. ohdaira@iuhw.ac.jp.Department of Surgery, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, Japan. yutaka@iuhw.ac.jp.Division of Molecular Epidemiology, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo 105-8461, Japan. urashima@jikei.ac.jp.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

31652554

Citation

Yonaga, Hideyuki, et al. "Effect Modification of Vitamin D Supplementation By Histopathological Characteristics On Survival of Patients With Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial." Nutrients, vol. 11, no. 10, 2019.
Yonaga H, Okada S, Akutsu T, et al. Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial. Nutrients. 2019;11(10).
Yonaga, H., Okada, S., Akutsu, T., Ohdaira, H., Suzuki, Y., & Urashima, M. (2019). Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial. Nutrients, 11(10). https://doi.org/10.3390/nu11102547
Yonaga H, et al. Effect Modification of Vitamin D Supplementation By Histopathological Characteristics On Survival of Patients With Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial. Nutrients. 2019 Oct 22;11(10) PubMed PMID: 31652554.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial. AU - Yonaga,Hideyuki, AU - Okada,Shinya, AU - Akutsu,Taisuke, AU - Ohdaira,Hironori, AU - Suzuki,Yutaka, AU - Urashima,Mitsuyoshi, Y1 - 2019/10/22/ PY - 2019/09/13/received PY - 2019/10/18/revised PY - 2019/10/21/accepted PY - 2019/10/27/entrez PY - 2019/10/28/pubmed PY - 2020/4/24/medline KW - Vitamin D KW - pathology KW - prognosis KW - supplementation KW - survival JF - Nutrients JO - Nutrients VL - 11 IS - 10 N2 - Some coauthors of this study previously performed the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2,000 IU/day) in 417 patients with stage I to III digestive tract cancer from the esophagus to the rectum who underwent curative surgery (UMIN000001977). We conducted a post-hoc analysis of the AMATERASU trial to explore the effects of modification of vitamin D supplementation by histopathological characteristics on survival. Among patients with poorly differentiated adenocarcinoma, the 5-year relapse-free survival rate of patients supplemented with vitamin D was 91% compared with 63% in the placebo group (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.08 to 0.78; P = 0.017; P for interaction = 0.023). Similarly, the 5-year overall survival rate was 92% in the vitamin D group compared with 72% in the placebo group (HR, 0.25; 95%CI, 0.07 to 0.94; P = 0.040; P for interaction = 0.012). In contrast, there were no significant effects in other histopathological characteristics between vitamin D and placebo groups. These findings generated the hypothesis that oral vitamin D supplementation may improve both relapse-free survival and overall survival in a subgroup of patients with poorly differentiated adenocarcinoma. SN - 2072-6643 UR - https://www.unboundmedicine.com/medline/citation/31652554/Effect_Modification_of_Vitamin_D_Supplementation_by_Histopathological_Characteristics_on_Survival_of_Patients_with_Digestive_Tract_Cancer:_Post_Hoc_Analysis_of_the_AMATERASU_Randomized_Clinical_Trial_ L2 - http://www.mdpi.com/resolver?pii=nu11102547 DB - PRIME DP - Unbound Medicine ER -